AV Therapeutics Announces Information Available Through S&P's Corporation Records Program

NEW YORK, Jan. 22, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced that its company information is now available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of AV Therapeutics was published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.

The company information about AV Therapeutics to be made available through this program includes an in-depth description of the AV Therapeutics' business operations, share price, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

About AV Therapeutics, Inc.

AV Therapeutics, Inc. is engaged in the business of developing cancer therapeutics and immunotherapeutic vaccines that can be used alone or in combination with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. The Company's immune-therapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram an immune system that can target previously unidentified micro-metastases. The Company intends to clinically develop both of these approaches for metastatic and early-stage prostate cancer.

About S&P Capital IQ

S&P Capital IQ, a business line of The McGraw-Hill Companies, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit www.spcapitaliq.com.

Company information distributed through the Corporation Records Program is based upon information that S&P Capital IQ considers to be reliable, but neither S&P Capital IQ nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

CONTACT: Jon Cunningham RedChip Companies, Inc. Tel: 1-800-RED-CHIP (733-2447), ext. 107 Email: info@redchip.comSource:AV Therapeutics, Inc.